Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 11:19:38 2023-12-05 am EST			5-day change	1st Jan Change
143.56 ^USD	-0.41%		+4.37%	-10.82%

04:47pm	AbbVie, BigHat Biosciences Partner to Develop Therapeutic Antibodies Using AI	MT
03:21pm	Johnson & Johnson forecasts as much as 6% sales growth in 2024	RE

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History : Analyst Recommendations

b65503.JVlkeKbhAtpEFC8bon4xYQSpVlQhI4NM2Dkoe5ZREZ4.cxUrCOqnXa13chxo20YGF1XrORlRdrB-6lVaOtAWd_FSLAsN8dNWrnxuSA~68b615f978b163d25178051632649b66

Analyst Recommendations on AbbVie Inc.

Raymond James Adjusts Price Target on AbbVie to $181 From $177, Maintains Outperform Rating	Dec. 01	MT
ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms...	Dec. 01
ANALYST RECOMMENDATIONS : Abbvie, Burberry, Chevron, Cisco, M&S...	Nov. 16
Deutsche Bank Initiates Coverage on AbbVie With Hold Rating, $150 Price Target	Nov. 09	MT
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $193, Maintains Overweight Rating	Oct. 30	MT
Barclays Upgrades AbbVie to Overweight From Equalweight, Raises Price Target to $170 From $160	Oct. 30	MT
ANALYST RECOMMENDATIONS : AbbVie, AMD, Astrazeneca, HSBC, Live Nation...	Oct. 30
UBS Adjusts AbbVie Price Target to $150 From $157, Maintains Neutral Rating	Oct. 20	MT
Morgan Stanley Raises Price Target on AbbVie to $193 From $189, Maintains Overweight Rating	Oct. 11	MT
Raymond James Initiates AbbVie at Outperform Rating With $177 Price Target	Sep. 29	MT
William Blair Initiates AbbVie With Market Perform Rating	Jul. 25	MT
HSBC Initiates AbbVie With Buy Rating, $167 Price Target	Jul. 14	MT
UBS Adjusts AbbVie Price Target to $157 From $165, Maintains Neutral Rating	May. 01	MT
Guggenheim Adjusts AbbVie's Price Target to $171 From $172, Keeps Buy Rating	Apr. 28	MT
Wells Fargo Adjusts Price Target on AbbVie to $195 From $200, Maintains Overweight Rating	Apr. 28	MT
Morgan Stanley Adjusts AbbVie's Price Target to $182 From $181, Keeps Overweight Rating	Apr. 28	MT
UBS Adjusts AbbVie Price Target to $165 From $152, Maintains Neutral Rating	Apr. 25	MT
Morgan Stanley Adjusts Price Target on AbbVie to $181 From $178, Maintains Overweight Rating	Apr. 10	MT
Argus Research Downgrades AbbVie to Hold From Buy	Apr. 05	MT
Guggenheim Initiates AbbVie at Buy With $172 Price Target	Mar. 01	MT
Wolfe Research Downgrades AbbVie to Peer Perform From Outperform	Feb. 22	MT
Morgan Stanley Adjusts Price Target on AbbVie to $178 From $182, Maintains Overweight Rating	Feb. 10	MT
Atlantic Equities Adjusts AbbVie's Price Target to $154 From $157, Maintains Neutral Rating	Feb. 10	MT
SVB Securities Upgrades AbbVie to Market Perform From Underperform, Adjusts Price Target to $153 From $135	Feb. 10	MT
UBS Adjusts AbbVie's Price Target to $152 From $150, Maintains Neutral Rating	Feb. 10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

144.15USD

Average target price

167.35USD

Spread / Average Target

+16.09%

High Price Target

201USD

Spread / Highest target

+39.44%

Low Price Target

126USD

Spread / Lowest Target

-12.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Raymond James
Deutsche Bank Securities
Morgan Stanley
Barclays
UBS
William Blair & Co.
HSBC
Guggenheim
Wells Fargo Securities
Argus
Wolfe Research
Piper Sandler
Atlantic Equities
SVB Securities LLC
BMO Capital
Truist Securities
Credit Suisse
Societe Generale
Goldman Sachs
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
Mizuho Securities
SVB Leerink
Daiwa Securities
RBC Capital Markets

Ratings for AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar